The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Subscribe To Our Newsletter & Stay Updated
